Tarsus Pharmaceuticals, Inc.
Financials
Valuation Metrics
Tarsus Pharmaceuticals, Inc.'s Market Cap is $3.36B. At end of 2025 it was $3.50B. Ranked #1635 of 3,121 in US market (top 52%), #578 of 1,463 on NASDAQ (top 40%), #97 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.36B | US#1,635/3,121 Sec#97/266 |
| Revenue | $606M | US#2,177/3,121 Sec#71/266 |
| Net Income | $-46M | US—/3,121 Sec—/266 |
| Total Assets | $611M | US#2,695/3,121 Sec#141/266 |
| Net Assets | $347M | US#2,461/3,121 Sec#150/266 |
| Employees | 370 | US#2,364/3,121 Sec#101/266 |
| Value | ||
| P/B | 9.69x | US#2,614/3,121 Sec#194/266 |
| P/S | 5.54x | US#2,384/3,121 Sec#84/266 |
| FCF Yield | 1.83% | US#2,065/3,121 Sec#69/266 |
| Profitability | ||
| ROE | -13.40% | US#2,415/3,121 Sec#87/266 |
| ROA | -7.60% | US#2,611/3,121 Sec#94/266 |
| Op. Margin | -8.00% | US#2,527/3,121 Sec#95/266 |
| Revenue Growth | 105.17% | US#91/3,121 Sec#33/266 |
| Financial Health | ||
| Debt Ratio | 76.26% | US#844/3,121 Sec#154/266 |
| Total Debt | $89M | US#2,474/3,121 Sec#127/266 |
| FCF | $62M | US#1,911/3,121 Sec#66/266 |
| Cash | $205M | US#1,721/3,121 Sec#107/266 |
| Current Ratio | 3.20x | US#738/3,121 Sec#184/266 |
| Performance | ||
| 1Y Return | 44.53% | US#539/3,121 Sec#107/266 |
| 1M Return | 6.33% | US#211/3,121 Sec#24/266 |
| From 52W High | -14.68% | US#1,013/3,121 Sec#70/266 |
| 1Y MDD | -32.00% | US#1,557/3,121 Sec#101/266 |
| Trading | ||
| Volume | 602,311 shares | US#2,170/3,121 Sec#222/266 |
| Trading Value | $47M | US#1,558/3,121 Sec#120/266 |
| Per Share | ||
| EPS | $-1.08 | US—/3,121 Sec—/266 |
| BPS | $8.06 | US#2,000/3,121 Sec#88/266 |
Company Info
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.